Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Septerna, Inc. (SEPN)
Company Research
Source: Yahoo! Finance
Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support a Planned Operating Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today reported financial results for the third quarter ended September 30, 2024 and provided a portfolio overview and business highlights. “At Septerna, we recently celebrated two major milestones: our transition to a clinical-stage company with the initiation of our Phase 1 clinical trial for SEP-786, and our debut as a public company following a successful IPO,” said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. “Our Native Complex Platform™ has yielded a deep pipeline of oral small molecule programs, each offering a unique p
Show less
Read more
Impact Snapshot
Event Time:
SEPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SEPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SEPN alerts
High impacting Septerna, Inc. news events
Weekly update
A roundup of the hottest topics
SEPN
News
- Septerna, Inc. (NASDAQ: SEPN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.MarketBeat
- Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial OfficerGlobeNewswire
- Septerna to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Septerna Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Septerna, Inc. (NASDAQ: SEPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock.MarketBeat
SEPN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- 2/7/25 - Form 4
- SEPN's page on the SEC website